Business Wire

GREAT-WALL-MOTOR

5.6.2019 11:19:08 CEST | Business Wire | Press release

Share
CZ-11 WEY Meets with a Great Success of China’s First-ever Sea Launch

At 12:06 on June 5, 2019, CZ-11 Solid-fuel Space Launch Vehicle (CZ-11 WEY) sees its first sea launch on the Yellow Sea, successfully sending seven satellites into the preset orbit and ushering in a new era of CASC development. The leading Chinese luxury SUV brand WEY is the first business partner of CASC. Both parties jointly call this launch vehicle as “CZ-11 WEY”, which marks a new breakthrough in business model of CASC. In addition, the Joint Technology Innovation Center co-initiated by CASC and WEY aims to put technologies into practice in the fields of quality system and testing, autonomous driving technology, new materials application and hydrogen energy through steady progress, so that the aero technology can be readily available.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005423/en/

CZ-11 Space Launch Vehicle is the first and only type of solid-fuel launch vehicles in the CZ Launch Vehicle Family. It is nearly 21 meters long and 58 tons weigh. Boasting a take-off thrust of 120 tons, it can carry up to 500 kg of payloads into the sun-synchronous orbit at a height of 500 km. This sea launch of CZ-11 WEY crystallizes the breakthroughs in a number of key technologies, such as wireless remote control at the front and rear terminals, independent intelligent security control on launcher, aiming of mobile base launching on the sea. CZ-11 Space Launch Vehicle has not only achieved China’s first-ever sea launch and low-inclination launch, but also created a new launch mode for Chinese launch vehicles into the space.

In conjunction with this sea launch, CASC and WEY steadily advance technical exchanges and cooperation in two fields. Both parties will promote integration in four fields of quality system and testing, autonomous driving technology, new materials application and hydrogen energy. They are committed to strongly empowering the independent R&D and manufacturing and creating greater market opportunities and economic value for CASC. Moreover, through technology application in the automotive industry, the aerospace technology can be readily available.

It is worth mentioning that Creative Experience Activity of “Dialogue with Parallel Universe” is jointly held by WEY and CASC. Through digital transmitter mounted on CZ-11 WEY Satellite, the voices of many consumers are transmitted to the outer space in the form of electric wave to “dialogue across the space” with another themselves in parallel universe. Compared with the international program of “Send Your Name to Mars with NASA’s next Mars Rover”, this sea launch is such a magnificent feat that retains the peoples’ voices and names in the space earlier.

Contact:

Great Wall Motor Liu Jian +8618241766066 liujian@dsconsulting.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye